Inari Medical Past Earnings Performance
Past criteria checks 0/6
Inari Medical's earnings have been declining at an average annual rate of -63.8%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 28.9% per year.
Key information
-63.8%
Earnings growth rate
-61.8%
EPS growth rate
Medical Equipment Industry Growth | 4.3% |
Revenue growth rate | 28.9% |
Return on equity | -13.5% |
Net Margin | -10.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Inari Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 547 | -57 | 397 | 96 |
31 Mar 24 | 521 | -24 | 368 | 92 |
31 Dec 23 | 494 | -2 | 351 | 88 |
30 Sep 23 | 469 | -3 | 340 | 85 |
30 Jun 23 | 439 | -16 | 327 | 83 |
31 Mar 23 | 413 | -28 | 315 | 80 |
31 Dec 22 | 383 | -29 | 293 | 74 |
30 Sep 22 | 359 | -22 | 258 | 73 |
30 Jun 22 | 336 | -15 | 239 | 66 |
31 Mar 22 | 306 | -1 | 208 | 59 |
31 Dec 21 | 277 | 10 | 190 | 51 |
30 Sep 21 | 242 | 16 | 167 | 39 |
30 Jun 21 | 208 | 25 | 134 | 32 |
31 Mar 21 | 170 | 17 | 110 | 24 |
31 Dec 20 | 140 | 14 | 90 | 18 |
30 Sep 20 | 111 | 7 | 72 | 15 |
30 Jun 20 | 86 | 1 | 59 | 11 |
31 Mar 20 | 71 | 4 | 48 | 9 |
31 Dec 19 | 51 | -1 | 37 | 7 |
31 Dec 18 | 7 | -10 | 11 | 4 |
Quality Earnings: IM7 is currently unprofitable.
Growing Profit Margin: IM7 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IM7 is unprofitable, and losses have increased over the past 5 years at a rate of 63.8% per year.
Accelerating Growth: Unable to compare IM7's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IM7 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.2%).
Return on Equity
High ROE: IM7 has a negative Return on Equity (-13.46%), as it is currently unprofitable.